Jeffrey Heier, MD
Specialties
Languages Spoken
- English
Contact Information
Phone: 800-635-0489
Fax: 617-723-7028
NPI: 1578546917
Education
Undergraduate School
Brandeis University
Waltham, MA
Medical School
Boston University School of Medicine
Boston, MA
Internship
Fitzsimons Army Medical Center
Aurora, CA
Residency
Ophthalmology
Fitzsimons Army Medical Center
Aurora, CA
Fellowship
Glaucoma
New England Eye Center/Tufts University & Ophthalmic Consultants of Boston
Boston, MA
Bio
Jeffrey S Heier, MD, is the Director of the Vitreoretinal Service and Director of Retina Research at Ophthalmic Consultants of Boston (OCB), one of the largest multi-specialty ophthalmology practices in the United States. Dr. Heier served as Co-President & Medical Director from 2016-2020.
Dr. Heier received his medical degree from Boston University, completed an internship and residency at Fitzsimons Army Medical Center, and vitreoretinal fellowship at Ophthalmic Consultants of Boston/Tufts School of Medicine. He served as a physician in a Combat Support Hospital in the Persian Gulf War, where he was awarded a Bronze Star.
Dr. Heier is the President of the Retina Society and a member of the Executive Committee of the American Society of Retina Specialists. He is the Past President of the New England Ophthalmological Society and a member of the Macula Society.
Dr. Heier is one of the leading retinal clinical researchers in the country for new treatments in exudative and non-exudative macular degeneration, diabetic macular edema, venous occlusive disease, vitreoretinal surgical techniques and instrumentation, and diagnostic imaging of the retina. He has served as one of the national or international lead investigators on numerous landmark clinical trial programs, including the phase 3 trial of Pegcetacoplan for advanced dry AMD, ranibizumab and aflibercept for neovascular AMD, and the dexamethasone implant for retinal venous occlusive disease.
Dr. Heier serves as the Chair of multiple scientific advisory boards and steering committees, including programs for pegcetocoplan, elamipritide, and avacincapted for dry AMD. These programs could bring a much-needed treatment for this devastating disease.
Dr. Heier is a scientific advisor to many companies, devoted to the development of innovative treatments from the earliest stages of development through presentation to FDA panels. He lectures nationally and internationally, and has authored over 140 peer-reviewed works.
Certifications
- American Board of Ophthalmology – Board Certified
- American Academy of Ophthalmology – Member
- New England Ophthalmological Society – Member
- Massachusetts Medical Society – Member
- Macula Society – Member
- Retina Society – Member
- American Society of Retinal Specialists – Member
- Massachusetts Society of Eye Physicians and Surgeons – Member